A股異動 | 丸美股份(603983.SH)漲逾9% 發佈新產品疊加券商看好
格隆匯3月22日丨丸美股份(603983.SH)盤中觸及漲停後小幅回落,現報56.5元,漲幅9.2%,最新總市值227.03億。消息稱,與人體自身膠原蛋白氨基酸序列100%一致的“抗衰密匙”――全人源膠原蛋白,在3月20日由丸美股份重磅發佈。董事長孫懷慶表示,在全人源膠原蛋白原料生產能力上,丸美已達到噸級生產能力,未來希望達到“十噸級”生產能力。廣發證券指,公司主品牌特色鮮明,線下線上共同發展,“美麗法則”新品發展可期,預計公司20-22年歸母淨利潤分別為5.7億元、7億元、8.3億元,參考可比公司估值,給予21年42XPE,合理價值為73.08元/股,維持“增持”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.